OPKO Health (OPK) stock soared 7.64% in pre-market trading on Wednesday, following a significant announcement regarding a new research collaboration. The biotechnology company's shares reacted positively to news of its subsidiary, Modex Therapeutics, entering into a partnership with industry giant Regeneron.

The collaboration between Modex Therapeutics and Regeneron aims to develop multispecific antibodies for select therapeutic indications. This partnership represents a major step forward for OPKO Health, as it combines Modex's expertise with Regeneron's established presence in the biotechnology sector. Multispecific antibodies are at the forefront of modern therapeutic research, offering potential for more targeted and effective treatments across various diseases.

Investors appear to be optimistic about the potential outcomes of this collaboration. The development of new antibody therapies could open up significant revenue streams for OPKO Health in the future, while also enhancing its position in the competitive biotechnology market. As the pre-market surge indicates, the market views this partnership as a strong positive signal for OPKO Health's future prospects and innovative capabilities in the field of advanced therapeutics.